Long-term complex therapy of cardiovascular diseases (reduction of cardiovascular risk: hypolidemic and antihypertensive therapy). Combined preparations as a method of increasing treatment adherence


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The treatment of cardiovascular diseases continues to be an important public health problem. Antihypertensive, lipid-lowering, anti-diabetic and antiplatelet therapies are intended to significantly reduce the risk of cardiovascular complications and fatal events. In real clinical practice, however, the effectiveness of the preventive measures is insufficient. Despite the availability of new drugs, the treatment of cardiovascular diseases remains suboptimal. The high prevalence of people with multiple risk factors requires the use of treatment tactics based on a combination of drugs against various risk factors. Simplification of treatment regimen, the use of fixed-dose combinations, is one of the facets of increasing treatment adherence, which causes an increase in the effectiveness of long-term therapy.

全文:

受限制的访问

作者简介

T. Fofanova

FSBI SMRC of cardiology of RMH

Email: t.fofanova@yandex.ru
MD, Senior Scientist at the Scientific-Dispensary Department SRI of Cardiology n.a. A.L. Myasnikov

F. Ageyev

FSBI SMRC of cardiology of RMH

M. Smirnova

FSBI SMRC of cardiology of RMH

参考

  1. ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013;34:2159-219.
  2. Pagliaro B., Santolamazza C., Rubattu S., Volpe M. New therapies for arterial hypertension. Panminerva Med. 2016;58(1):34-47.
  3. Оганов Р.Г., Масленникова Г.Я. Демографические тенденции в Российской Федерации: вклад болезней системы кровообращения. Кардиоваск. терапия и профилактика. 2012;1:5-10
  4. Raymundo N.A.C., Pierin A.M.G. Adherence to anti-hypertensive treatment within a chronic disease management program: A longitudinal, retrospective study. Rev. Esc. Enferm. USP. 2014;48(5):809-17
  5. Бойцов С.А., Хомицкая Ю.В. от имени группы исследователей CEPHEUS. Централизованное исследование по оценке эффективности лечения гиперхолестеринемии в России (CEPHEUS). Кардиоваск. терапия и профилактика. 2013;12(4):2-9.
  6. Wang B, Choudhry N.K., Gagne J.J., Landon J., Kesselheim A.S. Availability and utilization of cardiovascular fixed-dose combination drugs in the United States. Am. Heart J. 2015;169(3):379-86.
  7. Карпов Ю.А. Фиксированная комбинация периндоприла аргинина 10 мг и индапамида 2,5 мг в лечении плохо контролируемой артериальной гипертонии. Consilium Medicum. 2014;10(16):23-9.
  8. Borghi C., Omboni S. Zofenopril plus hydrochlorothiazide combination in the treatment of hypertension: an update. Expert. Rev. Cardiovasc. Ther. 2014;12(9):1055-65.
  9. Selak V., Elley C.R., Bullen C., Crengle S., Wadham A., Rafter N., Parag V., Harwood M., Doughty R.N., Arrol B., Milne R.J., Bramley D., Bryant L., Jackson R., Rodgers A. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomized controlled trial in primary care. BMJ. 2014;348:g3318.
  10. Dezii C.M. A retrospective study of persistence with single-pill combination therapy vs. Concurrent two-pill therapy in patients with hypertension. Manag. Care. 2000; 9(Suppl.):2-6.
  11. Агеев Ф.Т., Дробижев М.Б., Смирнова М.Д., Фофанова Т.В., Плисюк А.Г., Кадушина Е.Б. Свободная или фиксированная комбинация эналаприла и гидрохлоротиазида в реальной амбулаторной практике: что лучше для больного артериальной гипертонией? Сравнение эффективности и приверженности лечению. Кардиология. 2008;5:10-5.
  12. Yagi S., Takashima A., Mitsugi M., Wada T., Hotchi J., Aihara K., Hara T., Ishida M., Fukuda D., Ise T., Yamaguchi K., Tobiume T., Iwase T., Yamada H., Soeki T., Wakatsuki T., Shimabukuro M., Akaike M., Sata M. Effect of combination tablets containing amlodipine 10 mg and irbesartan 100 mg on blood pressure and cardiovascular risk factors in patients with hypertension.Ther. Clin. Risk. Manag. 2015;11:83-8.
  13. Vlachopoulos C., Grammatikou V., Kallistratos M., Karagiannis A. Effectiveness of perindopril/ amlodipine fixed dose combination in everyday clinical practice: results from the EMERALD study. Curr. Med. Res. Opin. 2016;32(9): 1605-10.
  14. Simonyi G., Ferenci T., Medvegy M., Gasparics R., Finta E. One year persistence of free and fixed dose combinations of perindopril/amlodipine. Orv. Hetil. 2017;158(36):1421-25.
  15. Tung Y.C.,Huang Y.C., Wu L.S., Chang C.J., Chu PH. Medication compliance and clinical outcomes of fixed-dose combinations vs free combinations of an angiotensin II receptor blocker and a calcium channel blocker in hypertension treatment.J Clin Hypertens (Greenwich). 2017 May 30. [Epub ahead of print].
  16. Motozato K, Miura S, Shiga Y, Kusumoto T., Saku K. Efficacy and Safety of a Single-Pill Fixed-Dose Combination of Azilsartan and Amlodipine. J. Clin. Med. Res. 2016;8(12):888-92.
  17. Shuster J.E., Bleske B.E., Dorsch M.P Clinical utility of azilsartan-chlorthalidone fixed combination in the management of hypertension. Vasc. Health Risk Manag. 2012;8:381-87.
  18. Simonyi G. Benefits of Fixed Dose Combination of Ramipril/Amlodipine in Hypertensive Diabetic Patients: A Subgroup Analysis of RAMONA Trial. Chin. Med. J. (Engl). 2016;129(10):1224-28.
  19. Garcia Donaire J.A., Ruilope L.M. Trandolapril/ verapamil combination in hypertensive diabetic patients. Vasc. Health Risk Manag. 2007;3(1):77-82.
  20. Abdulsalim S., Peringadi Vayalil M., Miraj S.S. New fixed dose chemical combinations: the way forward for better diabetes type II management? Expert. Opin. Pharmacother. 2016 Oct 4. [Epub ahead of print].
  21. Simonyi G., Ferenci T. Medication adherence with the fixed combination of ramipril and amlodipine. Orv. Hetil. 2014;155(47):1882-88.
  22. Simonyi G., Ferenci T., Medvegy M., Gasparics R., Finta E. One year persistence of free and fixed dose combinations of perindopril/amlodipine. Orv. Hetil. 2017;158(36):1421-25.
  23. Simonyi G., Ferenci T. Ramipril plus amlodipine and lisinopril plus amlodipine fixed dose combinations and patient's adherence. Orv. Hetil. 2016;157(1):30-4.
  24. Глезер М.Г., Выгодин В.А., Авакян А.А., Прокофьева Е.Б. От лица участников исследования. Результаты российской Программы ЭКСПЕРТ (Постмаркетинговое наблюдение за ЭффеКтивностью и влиянием Препарата ЭкватоР на качество жизни у пациентов с артериальной гипертоний в амбулаТорной практике). Кардиология. 2014;54(3):15-22.
  25. Lawrence Gould A., Unniachan S., Wu D. Indirect treatment comparison between fixed-dose-combinations of amlodipine/losartan and amlodipine/valsartan in blood pressure control. Int. J. Clin. Pract. 2014;68(2):163-72.
  26. Чазова И.Е., Мартынюк Т.В. На пути к достижению целей лечения артериальной гипертонии: результаты открытой наблюдательной программы ЭСКУЛАП (эксфорж-клиническая безопасность и эффективность с использованием двойной комбинации антигипертензивных препаратов у пациентов с неконтролируемым артериальным давлением). Тер. архив. 2013;85(9):35-45.
  27. Czarnecka D., Koch E.M., Gottwald-Hostalek U. Benefits of a fixed-dose combination of bisoprolol and amlodipine in the treatment of hypertension in daily practice: results of more than 4000 patients. Curr. Med. Res. Opin. 2015;31(5):875-81.
  28. Gottwald-Hostalek U., Sun N., Barho C., Hildemann S. Management of Hypertension With a Fixed-Dose (Single-Pill) Combination of Bisoprolol and Amlodipine. Clin. Pharmacol. Drug Dev. 2017;6(1):9-18.
  29. Mazza A., Schiavon L., Zuin M., Lenti S., Ramazzina E., Rubello D., Casiglia E. Effects of the Antihypertensive Fixed-Dose Combinations on an Early Marker of Hypertensive Cardiac Damage in Subjects at Low Cardiovascular Risk. Am. J. Hypertens. 2016;29(8):969-75.
  30. Giles T.D., Weber M.A., Basile J., Gradman A.H., Bharucha D.B., Chen W., Pattathil M; NAC-MD-01 Study Investigators Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. Lancet. 2014;383(9932): 1889-98.
  31. Sander G.E., Fernandez C., Giles T.D. Fixed-dose combination therapy of nebivolol and valsartan for the treatment of hypertension. Expert. Rev. Cardiovasc. Ther. 2016;14(5):563-72.
  32. Paton D.M. Nebivolol/valsartan: Fixed-dose combination for treatment of hypertension. Drugs Today (Barc). 2017;53(1):19-26.
  33. Shiga Y., Miura S., Adachi S., Suematsu Y., Sugihara M., Iwata A., Yahiro E., Nishikawa H., Ogawa M., Saku K. Visit-to-Visit Variability and Seasonal Variation in Blood Pressure With Single-Pill Fixed-Dose Combinations of Angiotensin II Receptor Blocker/Calcium Channel Blocker and Angiotensin II Receptor Blocker/Diuretic in Hypertensive Patients. J. Clin. Med. Res. 2015;7(10):802-6.
  34. Агеев Ф.Т. Смирнова М.Д., Фофанова Т.В., Свирида О.Н., Михайлов Г.В., Коновалова Г.Г., Ланкин В.З., Ревич Б.А. Влияние фиксированной комбинации амлодипина и периндоприла (препарат Престанс) на механизмы тепловой адаптации у больных артериальной гипертонией. Системные гипертензии. 2014;3:16-21.
  35. Леонова М.В., Штейнберг Л.Л., Белоусов Ю.Б. и группа исследователей. Фармакоэпидемиология артериальной гипертонии в России: анализ приверженности врачей (по результатам исследования ПИФАГОР IV). Системные гипертензии. 2015;1:19-25.
  36. Volpe M., Tocci G. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic. Vasc. Health Risk Manag. 2012;8:371-80.
  37. Thomopoulos C., Katsimagklis G., Archontakis S., Skalis G., Makris T. Optimizing the management of uncontrolled hypertension: what do triple fixed- dose drug combinations add? Curr. Vasc. Pharmacol. 2017. Apr 14. [Epub ahead of print].
  38. Epstein B.J., Shah N.K., Borja-Hart N.L. Management of hypertension with fixed-dose triple-combination treatments. Ther. Adv. Cardiovasc. Dis. 2013;7(5):246-59.
  39. Scheen A.J., Lancellotti P., Krzesinski J.M. Fixed dose combination perindopril-indapamide-amlodipine (Triplixam) for the treatment of arterial hypertension. Rev. Med. Liege. 2014;69(10):565-70.
  40. Pall D., Szänto I., Szabo Z. Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. Clin. Drug Investig. 2014;34(10):701-8.
  41. Mazza A., Lenti S., Schiavon L., Sacco A.P., DellAvvocata F., Rigatelli G., Ramazzina E. Fixed-Dose Triple Combination of Antihypertensive Drugs Improves Blood Pressure Control: From Clinical Trials to Clinical Practice. Adv. Ther. 2017;34(4):975-85.
  42. Deeks E.D. Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension. Am. J. Cardiovasc. Drugs. 2009;9(6):411-18.
  43. Assaad-Khalil S.H., Najem R., Sison J., Kitchlew A.R., Cho B., Ueng K.C., DiTommaso S., Shete A. Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups. Vasc. Health Risk Manag. 2015;11:71-8.
  44. Huan Y., Townsend R. The single pill triple combination of aliskiren, amlodipine, and hydrochlorothiazide in the treatment of hypertension. Expert. Opin. Pharmacother. 2012;13(16):2409-15.
  45. Bramlage P., Ketelhut R., Fronk E.M., Wolf W.P., Smolnik R., Zemmrich C., Schmieder R.E. Clinical impact of patient adherence to a fixed-dose combination of olmesartan, amlodipine and hydrochlorothiazide. Clin. Drug Investig. 2014;34(6):403-11.
  46. Ivanovic B., Tadic M. Fixed combination of amlodipine/atorvastatin: from mechanisms to trials. J. Cardiovasc. Pharmacol. Ther. 2013;18(6):544-49.
  47. Карпов Ю.А. Тройная комбинация антигипертензивных и липидснижающих препаратов - эффективное снижение риска сердечно-сосудистых осложнений у пациентов с артериальной гипертонией. РМЖ. 2015;27: 1580-83.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##